| Name | Title | Contact Details |
|---|
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
The mission of EMHS (Eastern Maine Healthcare Systems) is to maintain and improve the health and well-being of the people of Maine through a well-organized network of local health care providers who together offer high quality, cost-effective services to their communities. EMHS will be nationally recognized as a model of excellence in healthcare.
Out-of-pocket healthcare expenses are on the rise, which means patients are having difficulty paying their share and providers are finding it difficult to collect from those patients. It`s a lose-lose situation. CarePayment offers a unique solution that helps patients meet their financial obligations and protect their financial health while helping providers stay financially healthy by reducing bad debt and improving cash flow.
McDougall Scientific Ltd is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dr. Katie Rodan and Dr. Kathy Fields met at Stanford University during their dermatology residency bonding over their personal struggles with acne and an understanding of how skin issues impact self-esteem and self-confidence. They combined their personal connection and professional expertise into a shared mission: to provide everyone with life-changing skincareTM that deliver real results! Today, Rodan + Fields has grown from its humble beginnings in Dr. Katie Rodan`s kitchen to the #1 skincare brand in the U.S. in 2016.* We combine our innovative products with a high-tech, high-touch approach, and as a result, more than a million customers have experienced the benefits of Rodan + Fields. We are transforming skincare, and we welcome your big ideas to fuel our ambitious growth plans! If you are looking for a life-changing career opportunity, we`ve got your prescription. At Rodan + Fields, you will be challenged to make an impact, inspired to do more, and rewarded for your contributions.